Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 218

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 218
---

the total mix of viewpoints and experience represented on the board of directors. Our Nominating and Corporate Governance Committee and board of directors evaluate each director in the context of the membership of the board of directors as a group,
with the objective of maintaining a board of directors that can best perpetuate the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of backgrounds and experiences in various
areas. In determining whether to recommend a director for re-election, the Nominating and Corporate Governance Committee also considers the director’s past attendance at meetings, participation in and
contribution to the activities of the board of directors and the Company and other qualifications and characteristics set forth in the charter of the Nominating and Corporate Governance Committee.

Although our board of directors does not maintain a specific policy with respect to board diversity, our board of directors believes that it should be a
diverse body, and its Nominating and Corporate Governance Committee considers a broad range of backgrounds and experiences. In addition, we intend to satisfy applicable laws and regulations regarding board composition, including the rules of the
Nasdaq Capital Market (“Nasdaq”) regarding “diverse” directors. In making determinations regarding nominations of directors, our Nominating and Corporate Governance Committee may take into account the benefits of diverse
viewpoints. Our board of directors’s Nominating and Corporate Governance Committee also considers these and other factors as it oversees the annual board of director and committee evaluations. After completing its review and evaluation of
director candidates, the Nominating and Corporate Governance Committee recommends to our board of directors the director nominees for selection.

Our
corporate governance guidelines also dictate that a majority of the board of directors be comprised of independent directors whom the board of directors has determined have no material relationship with Aadi and who are otherwise
“independent” directors under the published listing requirements of Nasdaq.

- 148 -

Board of Directors The directors and their respective biographical information as of January 20, 2025 are set forth below:

| Name                           |     | Age |     | Position(s)                                   |     | Director 
    Since |     | Board Class 
 / Term      
 Expiration  |
| Caley Castelein, M.D.          |     |  54 |     | Chairman of the Board                         |     |     2017 |     | I - 2027    |
| Neil Desai, Ph.D.              |     |  60 |     | Director